ClinicalTrials.gg
CompletedNCT04191486Updated Nov 20, 2026Results posted

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or Mild AD

A Phase 2 interventional study of T-817MA and Placebo in Mild Cognitive Impairment, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 37 sites in 7 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Cognitive Dysfunction with a site in Germany — 20 open to participants now, 27 under way, 5 of them phase 3. Cognitive Dysfunction · Germany.

Enrollment
24th of 75
221 · median 100
Started
2019
with 6 others
Phase 2
8 of 102
none open now
Registered
62nd of 102
by date

Among the 102 studies in Cognitive Dysfunction with a site in Germany, this one is the 24th largest by enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2019, is one of 8 in phase 2, and was the 62nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

20 of the 102 studies in Cognitive Dysfunction with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Cognitive Dysfunction with a site in Germany, or all of them as a file.
02

Study summary

Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or mild AD.

Secondary objectives are:

  1. To evaluate in patients on T-817MA and placebo:

    • cognitive function measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and working memory and attention domain as measured by the Cognitive Functional Composite (CFC).
    • AD-related biomarkers in CSF and plasma
    • imaging analysis using volumetric magnetic resonance imaging (vMRI)
    • alpha/theta ratio of the electroencephalogram (EEG)
  2. To evaluate the safety of T-817MA by clinical laboratory tests and adverse events (AEs).
  3. To evaluate the pharmacokinetics of T-817MA
03

Conditions studied

  • Mild Cognitive Impairment
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Female of non- or male, ages 50 to 80 years (inclusive)
  • MCI due to AD or mild AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria (Jack et al., 2018), with Mini Mental Status Examination () 24 to 30 (inclusive)
  • CSF results at Screening consistent with the presence of amyloid ß (Aß) and p-tau181 abnormality (≤1000 pg/ml for Aß, ≥19 pg/ml for p-tau181).
  • Taking stable dose of acetylcholinesterase (AChE) Inhibitor (donepezil, galantamine or rivastigmine) at least for 3 months prior to randomization, or not taking any AChE Inhibitors.

Key Exclusion Criteria:

  • MRI of the brain within the previous 2 years that showed pathology that would be inconsistent with a diagnosis of AD
  • Taking memantine
  • Any to lumbar puncture
  • Any contraindications to MRI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    T-817MA (448 mg)

    Drug: T-817MA

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugT-817 maleateStudies of T-817 maleateT-817 maleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.

  • DrugPlacebo

    Placebo once daily

06

What researchers measure

Primary outcomes

  1. The Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 78

    p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 78 value\]). The changes from Baseline to Week 78 (log\[Week 78 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 78 (Week 78 value/Baseline value).

    Time frame: Baseline to Week 78

Secondary outcomes

  1. The Change Ratio in the CSF p-tau181 From Baseline to Week 52

    p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 52 value\]). The changes from Baseline to Week 52 (log\[Week 52 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 (Week 52 value/Baseline value).

    Time frame: Baseline to Week 52

  2. The Change Ratio in the CSF p-tau217 From Baseline to Week 52 and 78

    p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  3. The Change Ratio in the CSF Total Tau From Baseline to Week 52 and 78

    Total tau was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  4. The Change Ratio in the CSF Amyloid ß (Aβ) 1-42 From Baseline to Week 52 and 78

    Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  5. The Change Ratio in the CSF Aβ1-40 From Baseline to Week 52 and 78

    Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  6. The Change in the CSF Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78

    Aβ1-42/Aβ1-40 ratio was evaluated as a marker for amyloid deposition in the brain.

    Time frame: Baseline to Week 52 and 78

  7. The Change Ratio in the CSF Neurofilament Light (NFL) From Baseline to Week 52 and 78

    NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  8. The Change Ratio in the CSF Neurogranin From Baseline to Week 52 and 78

    Neurogranin was evaluated as a marker for synaptic damage. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  9. The Change Ratio in the CSF YKL-40 From Baseline to Week 52 and 78

    YKL-40 was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  10. The Change Ratio in the Plasma p-tau181 From Baseline to Week 52 and 78

    p-Tau181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  11. The Change Ratio in the Plasma p-tau217 From Baseline to Week 52 and 78

    p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  12. The Change Ratio in the Plasma Aβ1-42 From Baseline to Week 52 and 78

    Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  13. The Change Ratio in the Plasma Aβ1-40 From Baseline to Week 52 and 78

    Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  14. The Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78

    Aβ1-42/Aβ1-40 was evaluated as a marker for amyloid deposition in the brain.

    Time frame: Baseline to Week 52 and 78

  15. The Change Ratio in the Plasma NFL From Baseline to Week 52 and 78

    NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  16. The Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78

    GFAP was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

    Time frame: Baseline to Week 52 and 78

  17. The Change in Cognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) From Baseline to Weeks 28, 52, and 78

    The CDR is a global rating scale for staging patients diagnosed with dementia. CDR is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), mild cognitive impairment (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3). The sum of these 6 areas, the CDR-sb score, range from 0 (perfect performance) to 18 (worse).

    Time frame: Baseline to Week 28, 52 and 78

  18. The Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78

    The CFC is expected to detect clinically relevant changes in early dementia stages of AD, and comprises cognitive and functional components. The cognitive composite is computed as a weighted z-score of all seven cognitive subtests: Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog; 3 subscores (Orientation, Word Recall, Word Recognition), range 0-30\], Digit Span Backward Task (range 0-12), Controlled Oral Word Association Test (1 point for each correct non-repeated word), Category Fluency Test (1 point for each correct unique animal), Digit Symbol Substitution Test (1 point for each correct substituted symbol). The functional component consists of the Amsterdam Instrumental Activity of Daily Living Questionnaire-short version (A-IADL-Q-SV) and the scoring is based on item response theory. The overall CFC score is computed as an equally weighted z-score of the overall cognitive composite and IADL latent trait z-score. (Continued to "Analysis Population Description")

    Time frame: Baseline to Week 28, 52 and 78

  19. The Change in Total Brain Volume (TBV) Measured by Volumetric Magnetic Resonance Imaging (vMRI) From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including mild cognitive impairment (MCI) and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  20. The Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  21. The Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  22. The Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  23. The Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  24. The Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  25. The Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78

    Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

    Time frame: Baseline to Week 52 and 78

  26. The Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78

    An EEG was derived at Baseline and at Weeks 52 and 78 to measure global relative power in the theta band (4 to 8 Hz). Relative theta power has been regarded as the most sensitive marker of EEG oscillatory activity in early AD. In addition, relative power in the alpha band (8 to 13 Hz) and alpha/theta ratio were evaluated. Alpha/theta ratio of the EEG has been reported as a new marker for AD.

    Time frame: Baseline to Week 52 and 78

  27. Population Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max)

    Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmax values of T-817 at steady state (Week 78) were derived and used as Css-max, and then summarized as statistics. Abbreviations of PK parameters are explained in the Analysis Population Description.

    Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.

  28. PPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min)

    Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmin values of T-817 at steady state (Week 78) were derived and used as Css-min, and then summarized as statistics.

    Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.

  29. PPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)

    Blood samples for PPK analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual AUC values of T-817 during a dosage interval at steady state (Week 78) were derived and used as AUCss-tau, and then summarized as statistics.

    Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.

  30. The Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)

    CSF/plasma Ratio = (Observed CSF concentration of T-817)/(Predicted plasma concentration of T-817). Although the study protocol stated that CSF samples would be collected at Weeks 52 and 78, the actual collections occurred at at least either of Week 52 or Week 78. When the CSF analytical sample at Week 78 was not obtained or the sampling date for Week 78 was not the last T-817 administration date before sampling, the sample at Week 52 or at the point of discontinuation was analyzed. When these samples were not collected closer to the last administration time than the sample at Week 78, the sample at Week 78 was analyzed. CSF concentrations at both of Week 52 and 78 were analyzed for one patient, resulting in a total of 78 data points from 77 individuals, including 28 at Week 52 and 50 at Week 78. Plasma concentrations were predicted by PPK analysis. Individual CSF/plasma ratios at either of Week 52 or/and 78 were derived, pooled and then summarized as statistics.

    Time frame: Between 11:00 AM and 2:00 PM on Week 52 and 78.

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneT-817MA 448 mgPlacebo
Started108113
Completed84104
Not completed249
Withdrew: Adverse event103
Withdrew: Death10
Withdrew: Lack of efficacy11
Withdrew: Physician decision10
Withdrew: Withdrawal by subject95
Withdrew: Noncompliance with study drug10
Withdrew: Other10

Outcome measures

PrimaryThe Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 78

p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 78 value\]). The changes from Baseline to Week 78 (log\[Week 78 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 78 (Week 78 value/Baseline value).

Time frame:
Baseline to Week 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 78
RatioT-817MA 448 mgPlacebo
The Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 780.954 ± 0.0220.951 ± 0.020
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9164 · Least squares mean difference: 1.003 · 95% CI 0.953 to 1.055The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF p-tau181 From Baseline to Week 52

p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 52 value\]). The changes from Baseline to Week 52 (log\[Week 52 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 (Week 52 value/Baseline value).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF p-tau181 From Baseline to Week 52
RatioT-817MA 448 mgPlacebo
The Change Ratio in the CSF p-tau181 From Baseline to Week 520.947 ± 0.0220.963 ± 0.020
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.5139 · Least squares mean difference: 0.984 · 95% CI 0.936 to 1.034The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF p-tau217 From Baseline to Week 52 and 78

p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF p-tau217 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.958 ± 0.0321.007 ± 0.032
Week 78 (log-transformed)0.953 ± 0.0350.971 ± 0.033
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.1716 · Least squares mean difference: 0.951 · 95% CI 0.886 to 1.022The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.6547 · Least squares mean difference: 0.982 · 95% CI 0.904 to 1.065The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF Total Tau From Baseline to Week 52 and 78

Total tau was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF Total Tau From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.971 ± 0.0230.967 ± 0.021
Week 78 (log-transformed)0.974 ± 0.0230.963 ± 0.021
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7900 · Least squares mean difference: 1.004 · 95% CI 0.954 to 1.057The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.6842 · Least squares mean difference: 1.011 · 95% CI 0.960 to 1.065The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF Amyloid ß (Aβ) 1-42 From Baseline to Week 52 and 78

Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF Amyloid ß (Aβ) 1-42 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.949 ± 0.0290.966 ± 0.027
Week 78 (log-transformed)0.941 ± 0.0280.944 ± 0.025
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.6106 · Least squares mean difference: 0.983 · 95% CI 0.919 to 1.051The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9210 · Least squares mean difference: 0.997 · 95% CI 0.935 to 1.063The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF Aβ1-40 From Baseline to Week 52 and 78

Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF Aβ1-40 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.812 ± 0.0580.774 ± 0.051
Week 78 (log-transformed)0.808 ± 0.0520.762 ± 0.045
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.5724 · Least squares mean difference: 1.049 · 95% CI 0.889 to 1.237The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.4189 · Least squares mean difference: 1.061 · 95% CI 0.918 to 1.225The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change in the CSF Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78

Aβ1-42/Aβ1-40 ratio was evaluated as a marker for amyloid deposition in the brain.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Change in the ratio
The Change in the CSF Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78
Change in the ratioT-817MA 448 mgPlacebo
Week 520.016 ± 0.2630.396 ± 0.245
Week 780.000 ± 0.0010.002 ± 0.001
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.29 · Least squares mean difference: -0.380 · 95% CI -1.089 to 0.328
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.33 · Least squares mean difference: -0.002 · 95% CI -0.005 to 0.002
SecondaryThe Change Ratio in the CSF Neurofilament Light (NFL) From Baseline to Week 52 and 78

NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF Neurofilament Light (NFL) From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.175 ± 0.0511.091 ± 0.045
Week 78 (log-transformed)1.113 ± 0.0431.118 ± 0.040
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.1492 · Least squares mean difference: 1.076 · 95% CI 0.974 to 1.190The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9215 · Least squares mean difference: 0.996 · 95% CI 0.915 to 1.084The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF Neurogranin From Baseline to Week 52 and 78

Neurogranin was evaluated as a marker for synaptic damage. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF Neurogranin From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.971 ± 0.0200.980 ± 0.019
Week 78 (log-transformed)0.945 ± 0.0220.967 ± 0.021
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7044 · Least squares mean difference: 0.992 · 95% CI 0.949 to 1.036The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9215 · Least squares mean difference: 0.977 · 95% CI 0.926 to 1.031The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the CSF YKL-40 From Baseline to Week 52 and 78

YKL-40 was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the CSF YKL-40 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.013 ± 0.0141.023 ± 0.013
Week 78 (log-transformed)1.043 ± 0.0161.024 ± 0.015
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.5397 · Least squares mean difference: 0.991 · 95% CI 0.962 to 1.021The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.2949 · Least squares mean difference: 1.019 · 95% CI 0.984 to 1.055The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the Plasma p-tau181 From Baseline to Week 52 and 78

p-Tau181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma p-tau181 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.079 ± 0.0441.069 ± 0.041
Week 78 (log-transformed)1.123 ± 0.0401.051 ± 0.035
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.8531 · Least squares mean difference: 1.009 · 95% CI 0.917 to 1.111The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0888 · Least squares mean difference: 1.069 · 95% CI 0.990 to 1.154The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the Plasma p-tau217 From Baseline to Week 52 and 78

p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma p-tau217 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.056 ± 0.0521.086 ± 0.050
Week 78 (log-transformed)1.137 ± 0.0501.063 ± 0.044
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.6202 · Least squares mean difference: 0.973 · 95% CI 0.871 to 1.086The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.1609 · Least squares mean difference: 1.070 · 95% CI 0.973 to 1.177The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the Plasma Aβ1-42 From Baseline to Week 52 and 78

Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma Aβ1-42 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)0.982 ± 0.0480.981 ± 0.045
Week 78 (log-transformed)1.024 ± 0.0311.023 ± 0.029
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9899 · Least squares mean difference: 1.001 · 95% CI 0.887 to 1.129The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9688 · Least squares mean difference: 1.001 · 95% CI 0.942 to 1.064The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the Plasma Aβ1-40 From Baseline to Week 52 and 78

Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma Aβ1-40 From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.020 ± 0.0450.971 ± 0.041
Week 78 (log-transformed)1.049 ± 0.0231.038 ± 0.021
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.3925 · Least squares mean difference: 1.051 · 95% CI 0.937 to 1.179The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.6525 · Least squares mean difference: 1.010 · 95% CI 0.966 to 1.056The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78

Aβ1-42/Aβ1-40 was evaluated as a marker for amyloid deposition in the brain.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Change in the ratio
The Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78
Change in the ratioT-817MA 448 mgPlacebo
Week 52-0.000 ± 0.0010.000 ± 0.001
Week 78-0.000 ± 0.0010.000 ± 0.001
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.37 · Least squares mean difference: -0.001 · 95% CI -0.003 to 0.001
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.38 · Least squares mean difference: -0.001 · 95% CI -0.002 to 0.001
SecondaryThe Change Ratio in the Plasma NFL From Baseline to Week 52 and 78

NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma NFL From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.185 ± 0.0471.083 ± 0.040
Week 78 (log-transformed)1.273 ± 0.0481.084 ± 0.039
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0475 · Least squares mean difference: 1.094 · 95% CI 1.001 to 1.196The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Least squares mean difference: 1.175 · 95% CI 1.081 to 1.276The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78

GFAP was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Ratio
The Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78
RatioT-817MA 448 mgPlacebo
Week 52 (log-transformed)1.035 ± 0.0321.042 ± 0.030
Week 78 (log-transformed)1.125 ± 0.0371.037 ± 0.032
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.8405 · Least squares mean difference: 0.993 · 95% CI 0.928 to 1.063The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0318 · Least squares mean difference: 1.085 · 95% CI 1.007 to 1.169The estimated value presented is exponentially converted least squares mean difference. Therefore, the estimated value can be interpreted as the ratio of T-817MA 448 mg to Placebo.
SecondaryThe Change in Cognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) From Baseline to Weeks 28, 52, and 78

The CDR is a global rating scale for staging patients diagnosed with dementia. CDR is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), mild cognitive impairment (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3). The sum of these 6 areas, the CDR-sb score, range from 0 (perfect performance) to 18 (worse).

Time frame:
Baseline to Week 28, 52 and 78
Reported as:
Least squares mean · score on a scale
The Change in Cognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) From Baseline to Weeks 28, 52, and 78
score on a scaleT-817MA 448 mgPlacebo
Week 280.46 ± 0.180.49 ± 0.17
Week 521.18 ± 0.231.03 ± 0.22
Week 781.53 ± 0.261.57 ± 0.24
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.87 · Least squares mean difference: -0.03 · 95% CI -0.43 to 0.36
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.60 · Least squares mean difference: 0.15 · 95% CI -0.41 to 0.71
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.89 · Least squares mean difference: -0.05 · 95% CI -0.68 to 0.59
SecondaryThe Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78

The CFC is expected to detect clinically relevant changes in early dementia stages of AD, and comprises cognitive and functional components. The cognitive composite is computed as a weighted z-score of all seven cognitive subtests: Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog; 3 subscores (Orientation, Word Recall, Word Recognition), range 0-30\], Digit Span Backward Task (range 0-12), Controlled Oral Word Association Test (1 point for each correct non-repeated word), Category Fluency Test (1 point for each correct unique animal), Digit Symbol Substitution Test (1 point for each correct substituted symbol). The functional component consists of the Amsterdam Instrumental Activity of Daily Living Questionnaire-short version (A-IADL-Q-SV) and the scoring is based on item response theory. The overall CFC score is computed as an equally weighted z-score of the overall cognitive composite and IADL latent trait z-score. (Continued to "Analysis Population Description")

Time frame:
Baseline to Week 28, 52 and 78
Reported as:
Least squares mean · z-score
The Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78
z-scoreT-817MA 448 mgPlacebo
Week 28-0.095 ± 0.044-0.092 ± 0.042
Week 52-0.201 ± 0.052-0.223 ± 0.050
Week 78-0.366 ± 0.056-0.362 ± 0.052
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9550 · Least squares mean difference: -0.003 · 95% CI -0.095 to 0.090
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7206 · Least squares mean difference: 0.022 · 95% CI -0.097 to 0.140
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.9434 · Least squares mean difference: -0.005 · 95% CI -0.134 to 0.125
SecondaryThe Change in Total Brain Volume (TBV) Measured by Volumetric Magnetic Resonance Imaging (vMRI) From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including mild cognitive impairment (MCI) and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm^3
The Change in Total Brain Volume (TBV) Measured by Volumetric Magnetic Resonance Imaging (vMRI) From Baseline to Weeks 52, and 78
mm^3T-817MA 448 mgPlacebo
Week 52-14761 ± 1164.3-12115 ± 1066.1
Week 78-20881 ± 1363.5-17892 ± 1233.1
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0367 · Least squares mean difference: -2646 · 95% CI -5127 to -165.2
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0583 · Least squares mean difference: -2989 · 95% CI -6084 to 106.9
SecondaryThe Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm^3
The Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78
mm^3T-817MA 448 mgPlacebo
Week 525033.6 ± 378.83630.1 ± 346.9
Week 787002.8 ± 438.75412.9 ± 388.2
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0084 · Least squares mean difference: 1403.6 · 95% CI 470.9 to 2336.2
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0020 · Least squares mean difference: 1589.9 · 95% CI 607.6 to 2572.2
SecondaryThe Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm^3
The Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78
mm^3T-817MA 448 mgPlacebo
Week 52-120.3 ± 13.2-107.9 ± 12.1
Week 78-160.6 ± 15.6-130.0 ± 14.0
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.3898 · Least squares mean difference: -12.3 · 95% CI -40.6 to 15.9
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0903 · Least squares mean difference: -30.5 · 95% CI -65.9 to 4.8
SecondaryThe Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm
The Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78
mmT-817MA 448 mgPlacebo
Week 52-0.045 ± 0.004-0.041 ± 0.003
Week 78-0.063 ± 0.004-0.057 ± 0.004
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.2881 · Least squares mean difference: -0.004 · 95% CI -0.011 to 0.003
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.1846 · Least squares mean difference: -0.006 · 95% CI -0.015 to 0.003
SecondaryThe Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm
The Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78
mmT-817MA 448 mgPlacebo
Week 52-0.118 ± 0.007-0.091 ± 0.007
Week 78-0.158 ± 0.009-0.142 ± 0.008
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.0007 · Least squares mean difference: -0.027 · 95% CI -0.043 to -0.012
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.1717 · Least squares mean difference: -0.015 · 95% CI -0.037 to 0.007
SecondaryThe Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm
The Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78
mmT-817MA 448 mgPlacebo
Week 52-0.056 ± 0.005-0.049 ± 0.005
Week 78-0.077 ± 0.006-0.072 ± 0.005
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.2020 · Least squares mean difference: -0.007 · 95% CI -0.018 to 0.004
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.4265 · Least squares mean difference: -0.005 · 95% CI -0.019 to 0.008
SecondaryThe Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78

Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · mm
The Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78
mmT-817MA 448 mgPlacebo
Week 52-0.042 ± 0.005-0.040 ± 0.004
Week 78-0.058 ± 0.005-0.056 ± 0.004
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7172 · Least squares mean difference: -0.002 · 95% CI -0.011 to 0.008
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.8026 · Least squares mean difference: -0.001 · 95% CI -0.012 to 0.009
SecondaryThe Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78

An EEG was derived at Baseline and at Weeks 52 and 78 to measure global relative power in the theta band (4 to 8 Hz). Relative theta power has been regarded as the most sensitive marker of EEG oscillatory activity in early AD. In addition, relative power in the alpha band (8 to 13 Hz) and alpha/theta ratio were evaluated. Alpha/theta ratio of the EEG has been reported as a new marker for AD.

Time frame:
Baseline to Week 52 and 78
Reported as:
Least squares mean · Change in the ratio
The Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78
Change in the ratioT-817MA 448 mgPlacebo
Week 520.031 ± 0.0120.026 ± 0.011
Week 780.042 ± 0.0120.047 ± 0.011
Statistical analysis
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7171 · Least squares mean difference: 0.005 · 95% CI -0.022 to 0.032
  • T-817MA 448 mg vs Placebo · Mixed Models Analysis · p = 0.7156 · Least squares mean difference: -0.005 · 95% CI -0.030 to 0.020
SecondaryPopulation Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max)

Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmax values of T-817 at steady state (Week 78) were derived and used as Css-max, and then summarized as statistics. Abbreviations of PK parameters are explained in the Analysis Population Description.

Time frame:
Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
Reported as:
Mean · ng/mL
Population Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max)
ng/mLT-817MA 448 mg
Population Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max)612.36 ± 235.96
SecondaryPPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min)

Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmin values of T-817 at steady state (Week 78) were derived and used as Css-min, and then summarized as statistics.

Time frame:
Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
Reported as:
Mean · ng/mL
PPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min)
ng/mLT-817MA 448 mg
PPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min)118.13 ± 124.33
SecondaryPPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)

Blood samples for PPK analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual AUC values of T-817 during a dosage interval at steady state (Week 78) were derived and used as AUCss-tau, and then summarized as statistics.

Time frame:
Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
Reported as:
Mean · ng*hr/mL
PPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)
ng*hr/mLT-817MA 448 mg
PPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)7035.13 ± 3572.12
SecondaryThe Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)

CSF/plasma Ratio = (Observed CSF concentration of T-817)/(Predicted plasma concentration of T-817). Although the study protocol stated that CSF samples would be collected at Weeks 52 and 78, the actual collections occurred at at least either of Week 52 or Week 78. When the CSF analytical sample at Week 78 was not obtained or the sampling date for Week 78 was not the last T-817 administration date before sampling, the sample at Week 52 or at the point of discontinuation was analyzed. When these samples were not collected closer to the last administration time than the sample at Week 78, the sample at Week 78 was analyzed. CSF concentrations at both of Week 52 and 78 were analyzed for one patient, resulting in a total of 78 data points from 77 individuals, including 28 at Week 52 and 50 at Week 78. Plasma concentrations were predicted by PPK analysis. Individual CSF/plasma ratios at either of Week 52 or/and 78 were derived, pooled and then summarized as statistics.

Time frame:
Between 11:00 AM and 2:00 PM on Week 52 and 78.
Reported as:
Mean · Ratio
The Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)
RatioT-817MA 448 mg
The Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)0.163 ± 0.166

Adverse events

Collected over Screening to Week 82. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-817MA 448 mg1/108 (0.9%)16/108 (14.8%)49/108 (45.4%)
Placebo0/113 (0%)14/113 (12.4%)41/113 (36.3%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventT-817MA 448 mgPlacebo
PneumoniaInfections and infestations2/1080/113
Anal abscessInfections and infestations1/1080/113
GastroenteritisInfections and infestations1/1080/113
MeningitisInfections and infestations1/1080/113
Femoral neck fractureInjury, poisoning and procedural complications1/1080/113
FractureInjury, poisoning and procedural complications1/1080/113
Hand fractureInjury, poisoning and procedural complications1/1080/113
Hip fractureInjury, poisoning and procedural complications1/1080/113
Joint dislocationInjury, poisoning and procedural complications1/1080/113
Pelvic fractureInjury, poisoning and procedural complications1/1080/113
Most frequent other events
Most frequent other events
EventT-817MA 448 mgPlacebo
DiarrhoeaGastrointestinal disorders18/1088/113
COVID-19Infections and infestations18/10818/113
HeadacheNervous system disorders8/1089/113
NauseaGastrointestinal disorders6/1088/113
Urinary tract infectionInfections and infestations6/1087/113
DizzinessNervous system disorders3/1087/113
VertigoEar and labyrinth disorders6/1082/113

Baseline characteristics

Age, Continuous
Age, Continuous(years)T-817MA 448 mgPlaceboTotal
Mean70.3 ± 6.169.2 ± 6.969.7 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)T-817MA 448 mgPlaceboTotal
Female6370133
Male454388
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T-817MA 448 mgPlaceboTotal
Hispanic or Latino134
Not Hispanic or Latino107109216
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T-817MA 448 mgPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White108113221
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)T-817MA 448 mgPlaceboTotal
Netherlands151631
Czechia202242
Ireland336
United Kingdom9918
Germany242650
Spain373774
Mini Mental Scale Examination (MMSE) Score
Mini Mental Scale Examination (MMSE) Score(Score on a scale)T-817MA 448 mgPlaceboTotal
Mean26.7 ± 1.826.6 ± 1.826.6 ± 1.8
Apolipoprotein E (ApoE) type
Apolipoprotein E (ApoE) type(Participants)T-817MA 448 mgPlaceboTotal
E2/E2011
E2/E3213
E2/E4202
E3/E3293665
E3/E46060120
E4/E4151530
08

Study locations

37 sites
  • FNUSA - Mezinarodni centrum klinickeho vyzkumu
    Brno, Czechia
  • FNHK - Neurologicka klinika
    Hradec Králové, Czechia
  • A-shine, s.r.o.
    Pilsen, Czechia
  • CLINTRIAL, s.r.o.
    Prague, Czechia
  • VESTRACLINICS, s.r.o.
    Rychnov, Czechia
  • Klinik für Psychiatrie, Psychosomatik und Psychotherapie Universitätsklinikum Frankfurt
    Frankfurt, Germany
  • Klinik für Neurologie Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Klinik und Poliklinik für Neurologie Universitätsklinikum Leipzig
    Leipzig, Germany
  • Universitätsklinikum Magdeburg Institut für Kognitive Neurologie und Demenzforschung
    Magdeburg, Germany
  • Institut für Studien zur Psychischen Gesundheit (ISPG)
    Mannheim, Germany
  • Technische Universität München
    München, Germany
  • Universitätsklinikum Münster Klinik für Allgemeine Neurologie
    Münster, Germany
  • Universitätsmedizin Rostock Zentrum für Nervenheilkunde Klinik für Psychosomatik und Psychotherapeutische Medizin
    Rostock, Germany
  • Universitätsklinikum Ulm Studienzentrum Klinik für Neurologie
    Ulm, Germany
  • Debreceni Egyetem KK, Pszichiátriai Klinika
    Budapest, Hungary
  • Jávorszky Ödön Városi Kórház, Gyógyszertár
    Debrecen, Hungary
  • Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika
    Győr, Hungary
  • Semmelweis Egyetem Neurológiai Klinika Gyógyszertára, C földszint
    Vác, Hungary
  • St. Vincent's University Hospital
    Dublin, Ireland
  • Tallaght University Hospital.
    Dublin, Ireland
  • Brain Research Center Den Bosch
    's-Hertogenbosch, Netherlands
  • Brain Research Center
    Amsterdam, Netherlands
  • Amphia ziekenhuis
    Breda, Netherlands
  • Isala ziekenhuis
    Zwolle, Netherlands
  • Hospital General Universitari d' Elx
    Alicante, Spain
  • Fundació ACE
    Barcelona, Spain
  • Àrea Gestió Documentació Assaigs Clínics-AGDAC Hospital Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Clínico Universitario Virgen de La Arrixaca
    El Palmar, Spain
  • CAE Oroitu
    Getxo, Spain
  • Complejo Asistencial Universitario de Salamanca
    Salamanca, Spain
  • Hospital Victoria Eugenia - Cruz Roja
    Seville, Spain
  • Hospital Viamed Montecanal
    Zaragoza, Spain
  • University of Bath
    Bath, United Kingdom
  • Southmead Hospital North Bristol NHS Trust
    Bristol, United Kingdom
  • Glasgow memory Clinic
    Glasgow, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, United Kingdom
  • Memory Assessment & Research Centre
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Details for sharing data have not been decided yet.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Feb 2023, 37 months.

Results were first posted in Nov 2026, 3 years 8 months after primary completion.

Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 37 months is above that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2019
First posted
Dec 9, 2019
StartActual
Dec 24, 2019
Primary completionActual
Feb 22, 2023
CompletionActual
Mar 20, 2023
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Czechia, 1 Spain)
  • A-shine, s.r.o. · Pilsen, Czechia
  • Hospital Victoria Eugenia - Cruz Roja · Seville, Spain
Show 2 removed
  • A-shine, s.r.o. · Plzen, Czechia
  • Hospital Victoria Eugenia - Cruz Roja · Sevilla, Spain
Nov 20, 2026
Eligibility
3 criteria edited
What changed in the criteria
  • EditedMCI due to AD or mild AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria (Jack et al., 2018), with Mini Mental Status Examination (MMSE) 24 to 30 (inclusive)
  • EditedCSF results at Screening consistent with the presence of amyloid ß (Aß) and p-tau181 abnormality (≤1000 pg/ml for Aß, ≥19 pg/ml for p-tau181).
  • EditedTaking stable dose of acetylcholinesterase (AChE) Inhibitor (donepezil, galantamine or rivastigmine) at least for 3 months prior to randomization, or not taking any AChE Inhibitors.
Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe changeChange Ratio in the Cerebrospinal Fluid (CSF) p-tau181 fromFrom Baseline to Week 78Time frame: Baseline to Week 78
Nov 20, 2026
Documents
Secondary outcomes
17 edited, 13 added, 2 more
What changed in the outcomes
  • EditedThe changeChange Ratio in the CSF p-tau181 fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • EditedThe changeChange Ratio in the CSF p-tau217 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF total tau fromTotal Tau From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF Aβ1Amyloid ß (Aβ) 1-42 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF Aβ1-40 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange in the CSF neurofilament light (NFL) fromAβ1-42/Aβ1-40 Ratio From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF neurogranin fromNeurofilament Light (NFL) From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF YKL-40 fromNeurogranin From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the CSF Aβ1-42/Aβ1YKL-40 ratio fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the plasma Aβ1Plasma p-42 fromtau181 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the plasma Aβ1Plasma p-40 fromtau217 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in the plasma NFL fromPlasma Aβ1-42 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange in cognitive function assessedCognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb and working memory and attention domain as measured by the CFC from) From Baseline to Weeks 28, 52, and 78Time frame: Baseline to Weeks 28, 52 and 78 → Baseline to Week 28, 52 and 78
  • EditedThe changeChange in brain volume (total brain volumeTotal Brain Volume (TBV), ventricular volume and hippocampal volume) and cortical thickness measured Measured by Volumetric Magnetic Resonance Imaging (vMRI from) From Baseline to Weeks 52, and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedThe changeChange Ratio in alpha/theta ratio measured by the EEG fromPlasma Aβ1-40 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
  • EditedPopulation Pharmacokinetic (PK analysis) Analysis of T-817MA with assessmentWith Assessment of maximum plasma concentrationMaximum Plasma Concentration at Steady State (CmaxCss-max)Time frame: Weeks 16, 28, 40, and 65 → Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
  • EditedPopulation PK analysisPPK Analysis of T-817MA with assessmentWith Assessment of minimum plasma concentrationMinimum Plasma Concentration at Steady State (CminCss-min)Time frame: Weeks 16, 28, 40, and 65 → Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
  • AddedThe Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change Ratio in the Plasma NFL From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78Time frame: Baseline to Week 28, 52 and 78
  • AddedThe Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedThe Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
  • AddedPPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
  • AddedThe Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)Time frame: Between 11:00 AM and 2:00 PM on Week 52 and 78.
  • …and 2 more, on the record history on ClinicalTrials.gov ↗
Nov 20, 2026
Title
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or Mild AD
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (1 Czechia, 1 Spain)
    • A-shine, s.r.o. · Pilsen, Czechia
    • Hospital Victoria Eugenia - Cruz Roja · Seville, Spain
    Show 2 removed
    • A-shine, s.r.o. · Plzen, Czechia
    • Hospital Victoria Eugenia - Cruz Roja · Sevilla, Spain
    Eligibility 3 criteria edited
    What changed in the criteria
    • EditedMCI due to AD or mild AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria (Jack et al., 2018), with Mini Mental Status Examination (MMSE) 24 to 30 (inclusive)
    • EditedCSF results at Screening consistent with the presence of amyloid ß (Aß) and p-tau181 abnormality (≤1000 pg/ml for Aß, ≥19 pg/ml for p-tau181).
    • EditedTaking stable dose of acetylcholinesterase (AChE) Inhibitor (donepezil, galantamine or rivastigmine) at least for 3 months prior to randomization, or not taking any AChE Inhibitors.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe changeChange Ratio in the Cerebrospinal Fluid (CSF) p-tau181 fromFrom Baseline to Week 78Time frame: Baseline to Week 78
    Secondary outcomes 17 edited, 13 added, 2 more
    What changed in the outcomes
    • EditedThe changeChange Ratio in the CSF p-tau181 fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • EditedThe changeChange Ratio in the CSF p-tau217 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF total tau fromTotal Tau From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF Aβ1Amyloid ß (Aβ) 1-42 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF Aβ1-40 fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange in the CSF neurofilament light (NFL) fromAβ1-42/Aβ1-40 Ratio From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF neurogranin fromNeurofilament Light (NFL) From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF YKL-40 fromNeurogranin From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the CSF Aβ1-42/Aβ1YKL-40 ratio fromFrom Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the plasma Aβ1Plasma p-42 fromtau181 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the plasma Aβ1Plasma p-40 fromtau217 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in the plasma NFL fromPlasma Aβ1-42 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange in cognitive function assessedCognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb and working memory and attention domain as measured by the CFC from) From Baseline to Weeks 28, 52, and 78Time frame: Baseline to Weeks 28, 52 and 78 → Baseline to Week 28, 52 and 78
    • EditedThe changeChange in brain volume (total brain volumeTotal Brain Volume (TBV), ventricular volume and hippocampal volume) and cortical thickness measured Measured by Volumetric Magnetic Resonance Imaging (vMRI from) From Baseline to Weeks 52, and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedThe changeChange Ratio in alpha/theta ratio measured by the EEG fromPlasma Aβ1-40 From Baseline to WeeksWeek 52 and 78Time frame: Baseline to Weeks 52 and 78 → Baseline to Week 52 and 78
    • EditedPopulation Pharmacokinetic (PK analysis) Analysis of T-817MA with assessmentWith Assessment of maximum plasma concentrationMaximum Plasma Concentration at Steady State (CmaxCss-max)Time frame: Weeks 16, 28, 40, and 65 → Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
    • EditedPopulation PK analysisPPK Analysis of T-817MA with assessmentWith Assessment of minimum plasma concentrationMinimum Plasma Concentration at Steady State (CminCss-min)Time frame: Weeks 16, 28, 40, and 65 → Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
    • AddedThe Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change Ratio in the Plasma NFL From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78Time frame: Baseline to Week 28, 52 and 78
    • AddedThe Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedThe Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78Time frame: Baseline to Week 52 and 78
    • AddedPPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
    • AddedThe Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)Time frame: Between 11:00 AM and 2:00 PM on Week 52 and 78.
    • …and 2 more, on the record history on ClinicalTrials.gov ↗
    Title Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or Mild AD
    + 3 other changes: verification date, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04191486
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Dec 24, 2019
Primary completion
Feb 22, 2023
Completion
Mar 20, 2023
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Philip Scheltens, MD, PhD
study director · VUmc Alzheimer Centrum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T-817 maleate

Start the discussion